SHP Wealth Management’s Avadel Pharmaceuticals AVDL Stock Holding History

SHP Wealth Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,250	Closed	-$70K	–	1829
2025 Q4	$70K	Buy	+3,250	New	+$63.1K	0.01%	415

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

SHP Wealth Management's AVDL Position: Q1 2026 in Review

SHP Wealth Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 3,250 shares — an estimated $70K sold.

SHP Wealth Management first reported a position in AVDL in Q4 2025 and held it in 1 quarter. The position peaked at $70K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

SHP Wealth Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
SHP Wealth Management sold 3,250 Avadel Pharmaceuticals shares in Q1 2026, an estimated $70K.
SHP Wealth Management first reported a position in Avadel Pharmaceuticals in Q4 2025 and held it in 1 quarter.
SHP Wealth Management's Avadel Pharmaceuticals position peaked at $70K in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on SHP Wealth Management's 13F filing for Q1 2026, filed 8 May 2026.